Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 398, Issue 10317, Pages 2173-2184
Publisher
Elsevier BV
Online
2021-11-12
DOI
10.1016/s0140-6736(21)02000-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
- (2021) Pragya D. Yadav et al. Nature Communications
- Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation
- (2021) Brunda Ganneru et al. iScience
- Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
- (2021) Sreelekshmy Mohandas et al. iScience
- Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees
- (2021) Pragya D Yadav et al. CLINICAL INFECTIOUS DISEASES
- Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce
- (2021) Li Tang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
- (2021) Nawal Al Kaabi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin
- (2021) Pragya D Yadav et al. JOURNAL OF TRAVEL MEDICINE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Comparing vaccines: A systematic review of the use of the non-inferiority margin in vaccine trials
- (2015) R. Donken et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started